| Bioactivity | BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production[1]. |
| Target | Autophagy |
| Invitro | BRD5631 (10 μM, 48 hours) leads to increased levels of LC3-II in HeLa cells. BRD5631 stimulates formation of new autophagosomes, which is consistent with its ability to increase numbers of autolysosomes in the mCherry-GFP-LC3 assay[1].BRD5631 does not enhance autophagy by directly inhibiting mTOR or the mTOR signaling pathway. BRD5631 suppressed IL-1β secretion in an autophagy-dependent manner[1]. Cell Viability Assay[1] Cell Line: |
| Name | BRD5631 |
| CAS | 2446154-91-0 |
| Formula | C30H35N3O4 |
| Molar Mass | 501.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kuo SY, et al. Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4281-7. |